MBRXHealthcare · BiotechnologyThe 3 Wall Street analysts covering Moleculin Biotech, Inc. hold a median 12-month price target of $60 — +662.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 13 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Moleculin Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MBRX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +662.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $22 → $3.00 |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2025 | Maxim Group | Upgrade | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 12 Apr 2024 | Roth MKM | Maintains | Buy | — |
| 26 Mar 2024 | Maxim Group | Maintains | Buy | — |
| 14 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 18 Apr 2023 | Roth MKM | Maintains | Buy | — |
| 24 Mar 2023 | Oppenheimer | Reiterates | Outperform | — |
| 18 July 2022 | Oppenheimer | Assumes | Outperform | $14 |
| 17 Oct 2019 | Oppenheimer | Initiates | Outperform | $2.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MBRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 87% of US stocks
Cheaper than 63% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Moleculin Biotech, Inc. has a market value of $8.0M and an enterprise value of $694K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$30.3M.
Free cash flow in the twelve months to 30 June 2026: −$25.4M.
Trailing P/E: 0.0×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Moleculin Biotech, Inc. employs 17 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Moleculin Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Moleculin Biotech secured an Australian patent for its Annamycin formulation technology. The patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate.
Why it matters — The patent adds protection around a formulation technology relevant to Moleculin’s Annamycin program.
Preclinical data indicate that Annamycin-treated mice with pancreatic cancer had shorter survival when CD8+ T cells were inhibited, suggesting these immune cells contribute to Annamycin’s antitumor activity.
Why it matters — The findings point to a potential combination path involving Annamycin and checkpoint inhibitors or other immunotherapies.
Moleculin announced that Annamycin data have been accepted for presentation at the 2026 ASH Annual Meeting. The presentation will include first interim results from its pivotal Phase 2/3 trial, highlighting remission rates in patients with relapsed or refractory AML.
Why it matters — The accepted presentation will share interim trial findings on Annamycin in relapsed or refractory AML, a development of interest to MBRX watchers.
Moleculin Biotech reported that dosing is complete for patients in Part A of the pivotal MIRACLE Phase 2/3 trial evaluating Annamycin with cytarabine in relapsed or refractory AML. The company says a comprehensive data readout remains on track for Q1 2027.
Why it matters — Completion of Part A dosing marks a trial milestone, while the planned data readout timing is relevant to monitoring the program.
Moleculin released a new CEO Corner segment highlighting recent progress in the Annamycin MIRACLE trial. The source excerpt links to the segment.
Why it matters — The update provides MBRX watchers with a company communication about progress in its Annamycin MIRACLE trial.
The 3 Wall Street analysts covering Moleculin Biotech, Inc. have a median 12-month price target of $60, with estimates ranging from $40 to $620. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Moleculin Biotech, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Moleculin Biotech, Inc. 21 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Moleculin Biotech, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +662.4% from the last close, and Ticker Nerd's factor model ranks Moleculin Biotech, Inc. 21 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Moleculin Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $620 over the next 12 months.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat cancers and viral diseases.
The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Moleculin Secures Australian Patent for Annamycin Formulation Technology". Moleculin Biotech secured an Australian patent for its Annamycin formulation technology. The patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat cancers and viral diseases. Its leading program is Annamycin, also known as naxtarubicin, a next-generation anthracycline being evaluated in combination with cytarabine for adults with relapsed or refractory acute myeloid leukemia. The company’s research focuses on medicines designed to address treatment resistance and improve the delivery and tolerability of established anticancer approaches. Its oncology pipeline targets serious malignancies, while its broader development activities include antiviral applications and other disease areas where existing therapies remain limited. Moleculin Biotech, Inc. operates within the biotechnology and pharmaceutical market, collaborating across drug discovery, preclinical research, clinical development, regulatory activities, and potential commercialization. As a clinical-stage developer, its role is centered on advancing proprietary drug candidates through clinical testing rather than supplying marketed medicines across a broad commercial portfolio. The company is headquartered in Houston, Texas, and serves the specialized global market for innovative therapies addressing significant unmet medical needs.
CEO Mr. Walter V. Klemp · 17 employees · United States · https://moleculin.com